Showing 20 of 84 recruiting trials for “primary-plasmacytoma-of-the-bone”
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
👨⚕️ Enrique Ocio San Miguel, MD, PhD, Hospital Universitario Marqués de Valdecilla📍 11 sites📅 Started Jun 2023View details ↗
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
RecruitingNCT07111884 ↗
GMMG Multiple Myeloma Registry
👨⚕️ Hartmut Goldschmidt, Prof., University Hospital Heidelberg📍 35 sites📅 Started Dec 2022View details ↗
RecruitingNCT06659276 ↗
Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
👨⚕️ Ajay K. Nooka, MD,MPH,FACP, Emory University/Winship Cancer Institute📍 1 site📅 Started Jul 2022View details ↗
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
👨⚕️ Gunjan Shah, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started May 2022View details ↗
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
👨⚕️ Paula Rodríguez Otero, Clínica Universidad de Navarra📍 15 sites📅 Started Dec 2021View details ↗
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
👨⚕️ Shebli Atrash, MD, MS, Wake Forest University Health Sciences📍 2 sites📅 Started May 2021View details ↗
Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.
👨⚕️ Mikkel Andersen, Professor, Centre of Spine Surgery and Research, Middelfart Hospital📍 1 site📅 Started Mar 2021View details ↗
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
National Longitudinal Cohort of Hematological Diseases
RecruitingNCT05968417 ↗
Myeloma Novel Drug Discovery Ver 1.2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
👨⚕️ Lillian Siu, Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada📍 10 sites📅 Started Mar 2018View details ↗
RecruitingNCT03127761 ↗
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
👨⚕️ Anita D'Souza, MD, MS, CIBMTR, Medical College of Wisconsin📍 1 site📅 Started Jul 2017View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →